Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity (2010 - 2026)

Ani Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $1.4 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.4 billion, up 10.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 billion (up 17.31% YoY), and the FY2025 annual result was $1.4 billion, up 12.14% from the prior year.
• Liabilities and Shareholders Equity came in at $1.4 billion for Q1 2026 at Ani Pharmaceuticals, down from $1.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q4 2025 to a low of $739.1 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $914.5 million (2024), against an average of $1.0 billion.
• Peak annual rise in Liabilities and Shareholders Equity reached 60.58% in 2022, while the deepest fall reached 1.49% in 2022.
• Ani Pharmaceuticals' Liabilities and Shareholders Equity stood at $760.1 million in 2022, then gained by 18.99% to $904.4 million in 2023, then soared by 42.02% to $1.3 billion in 2024, then advanced by 12.14% to $1.4 billion in 2025, then decreased by 1.28% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.